|Videos|October 3, 2021

How To Prioritize Pediatric COVID-19 Vaccination

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

As COVID-19 vaccine regulations progress to younger and younger populations—with Pfizer-BioNTech and Moderna each seeking Emergency Use Authorization (EUA) based on data observing mRNA vaccines in patients as young as 5 years—the discussion turns from clinical benefit to patient prioritization.

Just as high-risk adult populations were prioritized for the first authorized vaccines, will a similar plan be put in place for children?

In an interview with Contagion during IDWeek 2021, Monica McArthur, MD, PhD, of the University of Maryland School of Medicine, discussed the progression of pediatric COVID-19 vaccination—a matter which in 2 years has shifted from a non-issue to a pressing priority.

“I think one of the most important things to note is that initially we were thinking that COVID-19 really wasn’t a big issue in the pediatric population,” McArthur said. It was only until a combination of factors including greater adult vaccination rates that pediatric cases began to climb.

McArthrur discussed the strategy of vaccine rollout and administration if and when vaccines become available to younger pediatric populations; the factors which influenced global health agencies to recommend older and high-risk adults receive the first available doses may not apply to children.

“Part of the concern with rollout for high-risk populations was vaccine scarcity, and I don’t think we’re faced with that as much anymore,” McArthur said. “My hope is that as soon as the vaccine becomes available under EUA for children aged 5-11 years old, it’d be available for all children.”

That said, children deemed to be at high risk of COVId-19 severity should still be targeted for safe, appropriate vaccination by direct caregivers, McArthur said.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.